#Brazil #São Paulo #MGI Tech #Personalized Medicine #Fiocruz

MGI Tech Strengthens Partnership with Fiocruz

MGI Tech Co., Ltd. has recently fortified its collaboration with the Diagnostic Support Unit (UNADIG) of the Oswaldo Cruz Foundation (Fiocruz), a prominent scientific institution in Brazil. This strategic partnership is focused on enhancing the nation's public health through advanced technologies in epidemiological surveillance and personalized medicine.

The roots of this collaboration trace back to the COVID-19 pandemic, during which MGI provided its MGISP-960 extractor, enabling UNADIG to successfully process over 3 million samples nationally. With the pandemic receding, UNADIG has broadened its laboratory capabilities, integrating various methodologies including chemiluminescence, Elisa, photometry, and genetic sequencing. The newly formed agreement will not only sustain the molecular tests such as RT-PCR but also pave the way for advancements in DNA-based testing.

Advancements in Laboratory Capacity

UNADIG operates two high-capacity laboratories, the Clinical Diagnostic Laboratory (DCLIN) and the Molecular Diagnostic Laboratory (DIMOL). The DCLIN processes around 29,000 samples daily, while DIMOL can handle between 9,000 to 15,000 RT-PCR samples. The partnership with MGI will propel a new phase in molecular genetics by enabling the weekly processing of over 2,000 samples aimed at diagnosing various infectious diseases and cancers, including breast, ovarian, colorectal, and prostate cancers, alongside gene sequencing for hereditary cases.

The goal of this collaboration, as stated by Carlos Carpio, MGI Latin America's Senior Commercial Director, is to transform the delivery of healthcare in Brazil, making complex laboratory tests more accessible and affordable. By improving the diagnostic speed and treatment of cancer and epidemic-related diseases, this partnership aims to strengthen Brazil’s public health response.

State-of-the-Art Technological Implementation

To bolster its operational capabilities, UNADIG has invested in cutting-edge equipment from MGI. This includes 14 units of the MGISP-960 nucleic acid extractor, the MGISP-100 automated genomic library preparation system, two DNBSEQ-G400 sequencers, one DNBSEQ-T7 sequencer, and the ZTRON platform for genomic data storage and analysis. These technologies promise not only enhanced speed and accuracy in testing but also improved safety in sample handling, thereby minimizing contamination risks.

Erika Martins de Carvalho, General Coordinator of UNADIG-RJ, expressed that precision medicine leads to significant benefits for patients and the public health system. It facilitates early diagnosis, more effective treatment protocols, and optimizes clinical processes, resulting in substantial cost savings and improved effectiveness of healthcare interventions. MGI's automation capabilities notably support these objectives.

Furthering Genetic Sequencing Accessibility

Expanding its influence in Brazil, MGI Tech is committed to making genetic sequencing more accessible and cost-effective. In 2024, the company launched a Customer Experience Center in São Paulo, designed to provide a hands-on environment for clinical laboratories and healthcare professionals to engage with MGI's technologies more closely. This initiative aims to enhance technical training through certified sessions led by qualified experts.

In addition to the Customer Experience Center, MGI has established partnerships with key players in the Brazilian healthcare sector, including Dasa, Grupo Sabin, and Oncoclínicas. These collaborations focus on the integration of advanced genetic testing technologies aimed at diagnosing cancer, rare diseases, and other health conditions—thus reinforcing the infrastructure for personalized medicine in Brazil.

About MGI Tech

Founded in 2016, MGI Tech Co., Ltd. is dedicated to developing essential tools and technologies that drive innovations in the life sciences sector. With a focus on research and development, manufacturing, and sales in biotechnology, MGI offers a comprehensive range of digital and omics solutions. The company has established itself as a global leader, providing advanced clinical-grade gene sequencers and life science technologies across multiple continents. With an ongoing commitment to revolutionizing healthcare, MGI aims to continue shaping the future of life sciences.

For further details, visit MGI Tech and explore their extensive range of innovative solutions.